Completion of Renounceable Rights Issue
Imagion Biosystems has announced the successful completion of the renounceable rights issue raising approximately $3.6 million. Read Imagion Biosystems' Right…
Imagion features in Mergermarkets
Imagion CEO Bob Proulx discusses the company's path to first-in-human trials plus early discussions with potential partners and strategic investors in this…
Mike Harsh Addresses Investors in Sydney, Australia
Non-Executive Director Mike Harsh addresses Imagion Biosystems' investors. November, 2019.
Finfeed interview with Mike Harsh
Interview: Mike Harsh on the evolution of Imaging and Imagion's role With over 40 years' experience in the health care diagnostic imaging industry, Imagion…
Bob Proulx Discusses Imagion's Recent Progress with Boardroom Media
Funds raised in Imagion’s recent Rights Issue will be used to fund the first-in-human trials for the Company’s MagSense technology. Listen to CEO Bob Proulx…
Imagion Biosystems' Patent Issued in India
Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, has been issued patent #320872 from…
Podcast: Board Member John Hazle and WE Communications Taryn Silver
In the first episode of the Imagion Biosystems podcast series, Board member Dr John Hazle speaks on his background, the imaging sector and how he came to join…
Imagion Biosystems Features on Morgans' Under the Microscope Podcast
Imagion Biosystems Limited (ASX: IBX) (the Company), had former GE Healthcare executive and Non-Executive Director, Mike Harsh, speak to Scott Power on the…
Offer Update and Appendix 3B
Imagion Biosystems Limited (ASX: IBX) (the Company) refers to its renounceable pro rata right issue offer of new fully paid ordinary shares (New Shares)…
Supplementary Prospectus
Imagion Biosystems Limited has announced a supplementary prospectus (Supplementary Prospectus) which shall be read with the prospectus dated 28 October 2019…